Fig. 4

hOM-MSC treatment downregulates MOG-specific IL-16 cytokine response during severe EAE. Antigen-specific peripheral inflammatory responses were measured from lymphocytes harvested from severe EAE mice at 5 days or 24 days post hOM-MSC, hBM-MSC or PBS injection (a timings shown by black arrows; T: treatment, Dy 5: Day 5, Dy24: Day 24). Isolated cells were stimulated with the MOG protein (1–125) and supernatants assayed using a 35 U-plex array. IL-16 levels within serum were assayed by ELISA. hOM-MSC animals had reduced MOG-specific IL-16 production in lymphocytes (b) and circulating serum (c) compared to PBS animals at day 5 but this was not sustained until day 24 (f, g).There were no significant differences in the levels of IFNγ or IL-17 (two of the main cytokines involved in T-cell mediated disease) at day 5 (d, e, respectively) or day 24 (h, i, respectively). PBS, n = 6; hOM-MSCs, 5; hBM-MSCs, n = 4, *p < 0.05, ANOVA, Tukey’s multiple comparison